title: Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia.
abstract: In patients with B-cell chronic lymphocytic leukemia (B-CLL), the absolute number of T cells is increased. Although it has been suggested that these T cells might be tumor specific, concrete evidence for this hypothesis is lacking. We performed a detailed immunophenotypic analysis of the T-cell compartment in the peripheral blood of 28 patients with B-CLL (Rai 0, n = 12; Rai I-II, n = 10; Rai III-IV, n = 6) and 12 healthy age-matched controls and measured the ability of these patients to mount specific immune responses. In all Rai stages a significant increase in the absolute numbers of CD3+ cells was observed. Whereas the number of CD4+ cells was not different from controls, patients with B-CLL showed significantly increased relative and absolute numbers of CD8+ cells, which exhibited a CD45RA+CD27- cytotoxic phenotype. Analysis of specific immune responses with tetrameric cytomegalovirus (CMV)-peptide complexes showed that patients with B-CLL had significantly increased numbers of tetramer-binding CMV-specific CD8+ T cells. The rise in the total number of CD8+ cytotoxic T cells was evident only in CMV-seropositive B-CLL patients. Thus, our data suggest that in patients with B-CLL the composition of T cells is shifted toward a CD8+ cytotoxic cell type in an effort to control infections with persistent viruses such as CMV. Moreover, they offer an explanation for the high incidence of CMV reactivation in CLL patients treated with T cell-depleting agents, such as the monoclonal antibody (mAb) alemtuzumab (Campath; alpha-CD52 mAb). Furthermore, because in CMV-seronegative patients no increase in cytotoxic CD8+ T cells is found, our studies do not support the hypothesis that tumor-specific T cells account for T-cell expansion in B-CLL.
authors.affiliation: Department of Hematology, Academic Medical Center, Rm F4-210, University of Amsterdam, PO Box 22660, 1100 DD Amsterdam, The Netherlands.
authors.forename: Wendelina J M
authors.initials: WJ
authors.lastname: Mackus
authors.forename: Florine N J
authors.initials: FN
authors.lastname: Frakking
authors.forename: Annette
authors.initials: A
authors.lastname: Grummels
authors.forename: Laila E
authors.initials: LE
authors.lastname: Gamadia
authors.forename: Godelieve J
authors.initials: GJ
authors.lastname: De Bree
authors.forename: Dorte
authors.initials: D
authors.lastname: Hamann
authors.forename: Rene A W
authors.initials: RA
authors.lastname: Van Lier
authors.forename: Marinus H J
authors.initials: MH
authors.lastname: Van Oers
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D016827:CD8 Antigens / Q000032:analysis; D016022:Case-Control Studies; D003587:Cytomegalovirus / Q000276:immunology*; D006801:Humans; D016130:Immunophenotyping; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology* / Q000821:virology*; D017493:Leukocyte Common Antigens / Q000032:analysis; D008213:Lymphocyte Activation / Q000276:immunology; D018655:Lymphocyte Count; D008875:Middle Aged; D016176:T-Lymphocyte Subsets; D013601:T-Lymphocytes / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7 / Q000032:analysis
chemical_list: D016827:CD8 Antigens; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7; D017493:Leukocyte Common Antigens